Recombinant Human SLAM/CD150 Fc Chimera Protein, CF

Name: Recombinant Human SLAM/CD150 Fc Chimera Protein, CF
Brand: R&D Systems
SKU: 11480-SL
Price: 454 USD
Availability: InStock

R&D Systems | Catalog # 11480-SL

Submit a review

Product Documents

SLAMF1

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

R&D Systems HEK293-derived Recombinant Human SLAM/CD150 Fc Chimera Protein (11480-SL)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

HEK293

Accession Number

Q13291.1

Applications

Bioactivity

View all SLAM/CD150 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human SLAM/CD150 protein

Human SLAM (Ala21-Lys236) Accession # Q13291.1	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala21,Tyr23,Thr25

Predicted Molecular Mass

51 kDa

SDS-PAGE

60-80 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
Recombinant Human SLAM/CD150 Fc Chimera binds to Biotinylated SLAM/CD150 protein with an ED₅₀ of 0.100-1.00 μg/mL.

Scientific Data Images for Recombinant Human SLAM/CD150 Fc Chimera Protein, CF

Recombinant Human SLAM/CD150 Fc Chimera Protein Binding Activity.

Recombinant Human SLAM/CD150 Fc Chimera Protein (Catalog # 11480-SL) binds to Biotinylated SLAM/CD150 protein with an ED₅₀ of 0.100-1.00 μg/mL.

Recombinant Human SLAM/CD150 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human SLAM/CD150 Fc Chimera Protein (Catalog # 11480-SL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-80 kDa and 120-160 kDa, respectively.

Formulation, Preparation, and Storage

11480-SL

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: SLAM/CD150

Signaling lymphocytic activation molecule (SLAM), also known as SLAMF1 and CD150, is the founding member of the SLAM subfamily of the CD2 protein family (1, 2). SLAM is a single-pass type I membrane glycoprotein that functions as an adhesion molecule and plays an active role in the regulation of innate and adaptive immunity (1, 2, 4). Mature SLAM consists of an extracellular domain (ECD) containing an Ig-like V-type domain and an Ig-like C2-type domain, a helical transmembrane domain, and a cytoplasmic tail containing 2 immunoreceptor tyrosine-based switch motifs (ITSM) (3, 4). The ECD of human SLAM shares human SLAM shares 58% and 56% amino acid sequence identity with mouse and rat SLAM, respectively.. In human, several isoforms resulting from alternative splicing have been identified with functional diversity (4). SLAM is expressed on T cells, B cells, thymocytes, macrophages, dendritic cells, platelets, and hematopoietic stem cells, and it is up-regulated on activated B cells and CD4+ and CD8+ T cells (4 – 6). SLAM interacts homophilically with low affinity, and this interaction induces a Th0/Th1 phenotype in CD8+ T cells that is characterized by clonal expansion, production of IFN-gamma, and increased cytolytic activity (7, 8). SLAM also plays a role in activation of the PI3K-Akt signaling pathway through its association with the adapter molecule SAP (9). In humans, SLAM functions as a cellular entry receptor for measles virus (10, 11). SLAM deregulation is associated with genomic complexity and independently predicts a worse outcome in chronic lymphocytic leukemia (CLL) (12).